medigraphic.com
ISSN 1561-3119 (Electronic)

2017, Number 2

<< Back Next >>

Rev Cubana Pediatr 2017; 89 (2)

The role of intestine in the health/disease process

Mena MVR

Language: Spanish
References: 30
Page: 203-213
PDF size: 180.34 Kb.


ABSTRACT

Introduction: Several decades ago, it was thought that the intestine's function was only related to the process of nutrition; however, it has been demonstrated that it also influences in the immune response and the systemic inflammation of the individual.
Objective: To describe the relationship of the different factors involved in the intestine's response in the health/disease process.
Method: A literature review was made in Medline/Pubmed, Elsevier and Scielo to find articles published in English and Spanish about the particularities of the intestine's response in the health/disease process in the period of 2011 through 2016. The search terms were intestinal ecosystem, intestinal permeability, bacterial translocation and oxidative stress.
Development: Due to the role of the intestine in the immune response and the systemic inflammation of the individual, this is considered a metabolically active organ in the health/disease process. The interrelation of these factors has an effect on the physiopathogeny of chronic diseases such as asthma, cancer, non-alcoholic fatty liver as well as in response and progress of the critically-ill patient.
Final thoughts: Changes in the composition of the intestinal microbiota, associated to disbiosis, increased intestinal permeability through zonuline, the oxidative stress, the bacterial translocation and the use of antibiotics in the critical patient are closely linked to a number of functions that are regulated from the intestine as part of the health/disease process.


REFERENCES

  1. Bushman FD, Lewis JD, Wu GD. Alimentación, enterotipos intestinales y salud: ¿existe una relación? En La importancia de la inmunonutricion: Nestle Nutrición Workshop. Suiza: Ed Nestec S A Vevey; 2012. p. 17-8.

  2. Icaza ME. Microbiota intestinal en salud y enfermedad. Rev Gastroenterol Mex. 2012;77(sup 1):23-5.

  3. Stephan C, Bischoff SC, Barbara G, Buurman W, Ockhuizen T, Schulzke JD, Serino M. Intestinal permeability-a new target for disease prevention and therapy. BMC Gastroenterology. 2014;14:189.

  4. Farías MM, Catalina Silva C, Rozowski J. Microbiota intestinal: rol en obesidad gut microbiota: role in obesity. Rev Chil Nutr. 2011;38:228-33.

  5. Devaraj S, Hemarajata P, Versalovic J. La microbiota intestinal humana y el metabolismo corporal: Implicaciones con la obesidad y la diabetes. Acta Bioquim Clin Latinoam. 2013;47(2):421-34.

  6. Gómez Duque M. Acero F Composición y funciones de la flora bacteriana intestinal. Repert Med Cir. 2011;20(2):74-82.

  7. Icaza C. Microbiota intestinal en la salud y la enfermedad. Rev Gastroenterología de México. 2013;78(4):240-8.

  8. Kwan Chan Y, Estaki MM, Gibson DL. Consecuencias clínicas de la disbiosis inducida por la dieta. Ann Nutr Metab. 2013;63(sup):28-40.

  9. Rondon L, Anez Zavala RM, Salvatierra Hidalgo A, Meneses Barrios RT, Heredia Rodríguez MT. Guías de manejo clínico: consenso de probióticos: generalidades. Archivos Venezolanos de Puericultura y Pediatría. 2015;78(4):123-8.

  10. Kristensen NB, Bryrup T, Allin KH, Nielsen T, Hansen TH, Pedersen O. Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: a systematic review of randomized controlled trials. Genome Medicine. 2016;8:52.

  11. Gotteland M. El papel de la microbiota intestinal en el desarrollo de la obesidad y de la diabetes de tipo-2. Rev Chil Endocrinol Diabetes. 2013;6(4):155-62.

  12. Odenwald MA, Turner JR. Intestinal permeability defects: Is it time to treat? Clin Gastroenterol Hepatol. 2013;11(9):1075-83.

  13. Holguín Cardona A, Hurtado Guerra JJ, Restrepo Gutiérrez JC. Una mirada actual a la peritonitis bacteriana espontánea. Rev Col Gastroenterol. 2015;30(3):315-23.

  14. Valdovinos D, Cadena J, Montijo E, Zárate F, Cazares M, Toro E, et al. Síndrome de intestino corto en niños: actualidades en su diagnóstico y manejo. Revista de Gastroenterología de México. 2012;77(3):130-40.

  15. Paños Melgoso MR, Álvarez Lerma F, Ramírez Galleymore P. Análisis de la alteración de la permeabilidad intestinal en pacientes con insuficiencia cardiaca aguda o crónica reagudizada [homepage en Internet]; Universidad Autónoma de Barcelona [citado 5 de Agosto de 2016]. Disponible en: https://ddd.uab.cat/pub/trerecpro/2012/hdl_2072_180158/TR-PanosMelagoso.pdf

  16. Salvo-Romero E, Alonso-Cotoner C, Pardo-Camacho C, Casado-Bedmar M, Vicario M. Función barrera intestinal y su implicación en enfermedades digestivas. Rev Esp Enf Dig. 2015;107(11):686-96.

  17. Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiological Reviews. 2011;91(1):151-75.

  18. Fasano A. Intestinal permeability and its regulation by zonulin: diagnostic and therapeutic implications. Clin Gastroenterol Hepatol. 2012;10(10):1096-100.

  19. Da Costa LA, Badawi A, El-Sohemy A. Nutrigenética y modulación del estrés oxidativo. Ann Nutr Meab. 2012;60(sup 3):27-36.

  20. Clemente-Postigo M, Queipo-Ortuno MI, Murri M, Boto Ordoñez M, Pérez Martínez P, Lacueva CA, et al. Endotoxin increase after fat overload is related to postprandial hypertriglyceridemia in morbidly obese patients. J Lipid Res. 2012;53:973-8.

  21. Singer M, Deutschman CS, Warren Seymuour C, Shankar-Hari M, Djillalu A, Bauer M, et al. The Third International Consensus Definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;375(8):801-10.

  22. Aller Reyero MA, Arias Pérez J, Aljabban Nieves A. Orbegozo Valdiviezo ST, Romero Valverde WM. Complicaciones de las quemaduras a nivel gastrointestinal. REDUCA Serie Congresos Alumnos. 2014;6(1):126-31.

  23. Carrillo E, Leon Valdivieso JY. Conceptos actuales suficiencia hepática aguda. Rev Invest Med Sur. 2012;19(2):76-8.

  24. Creely SJ, McTernan PG, Kuminski CM, Fisher FM, Da Silva NF, Khanolkar M. Lipopolysaccharide activates an innate immune system response in humana dipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab. 2007;292:E740-747.

  25. Shimizu K, Ogura H, Hamasaki T, Got M, Tasaki O, Asahara T, et al. Altered Gut Flora Are Associated with Septic Complications and Death in Critically Ill Patients with Systemic Inflammatory Response Syndrome. Dig Dis Sci. 2011;56:1171-7.

  26. Vargas de Velázquez M. Microbiota intestinal: importancia en el paciente crítico. IX Congreso Panameño de Medicina Critica, 6 Simposio Internacional de Neurointensivismo [homepage en Internet]; Panamá, 2016 [citado 20 de Agosto de 2016]. Disponible en: http://www.medcriticapanama.com/images/congreso2016/dias/martes/A20-MICROBIOTA%20INTESTINAL%20-Dra%20Vargas.pdf

  27. Latorre M, Krishnareddy S, Freedberg DE. Microbiome as mediador: do systemic infections star in the gut. World J Gastroenterol. 2015;21(37):10487-92.

  28. Mitral R, Coopersmith CM. Redefining the gut as the motor of crirtical illness. Tredz Mol Med. 2014;20(4):214-23.

  29. Dickson RP. The microbiome and criticall illness. Lancet Resp Med. 2016;4:59-72.

  30. Espera RC, Díaz Ponce JA, Peña Pérez CA, Flores Riverae OI, Maldonadoe RN, Zepeda Mendoza AD, et al. Especies reactivas de oxígeno, sepsis y teoría metabólica del choque séptico. Rev de la Fac de Med la UNAM. 2016;5(1):6-18.




2020     |     www.medigraphic.com